A08501 - Requires written notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination which includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.
New York - 2023-2024 General Assembly
Introduced byJohn T. McDonald
Last updated 8 months ago
1 Co-Sponsor
STATUS
Passed
Verifications Required
You must be a verified voter to do that.
No Thanks, I'll do it later
Verify your identity now